EML4-ALK mediated upregulation of PD-L1 provides a strategy to block PD-L1 as a treatment option in ALK-tyrosine kinase inhibitor resistant NSCLC [149]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.